Which has higher earnings & valuation, CYTK or VCEL?

Vericel has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 88.91 -$784.96M -$7.22 N/A Vericel $306.30M 6.70 $16.52M $0.47 85.32

Is CYTK or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Cytokinetics' net margin of -1,321.12%. Vericel's return on equity of 6.91% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -1,321.12% N/A -51.01% Vericel 7.91% 6.91% 5.02%

Does the media favor CYTK or VCEL?

In the previous week, Cytokinetics had 7 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Cytokinetics and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Cytokinetics' score of 0.40 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ABVX or VCEL?

Vericel has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$6.06 N/A Vericel $306.30M 6.70 $16.52M $0.47 85.32

Is ABVX or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Abivax's net margin of 0.00%. Vericel's return on equity of 6.91% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Vericel 7.91% 6.91% 5.02%

Does the media refer more to ABVX or VCEL?

In the previous week, Abivax and Abivax both had 4 articles in the media. Abivax's average media sentiment score of 1.32 beat Vericel's score of 0.99 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VCEL or PRAX?

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Praxis Precision Medicines' score of 0.24 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, VCEL or SYRE?

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $306.30M 6.70 $16.52M $0.47 85.32 Spyre Therapeutics $890K 9,811.99 -$155.20M -$1.95 N/A

Does the media prefer VCEL or SYRE?

In the previous week, Spyre Therapeutics had 18 more articles in the media than Vericel. MarketBeat recorded 22 mentions for Spyre Therapeutics and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Spyre Therapeutics' score of 0.25 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 6 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VCEL or IONS?

In the previous week, Ionis Pharmaceuticals had 1 more articles in the media than Vericel. MarketBeat recorded 5 mentions for Ionis Pharmaceuticals and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Ionis Pharmaceuticals' score of -0.14 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Vericel (VCEL) Competitors

$40.10 +0.05 (+0.12%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$40.06 -0.04 (-0.10%)

As of 10/9/2026 07:30 PM Eastern

Compare

VCEL vs. CYTK, ABVX, PRAX, SYRE, and IONS

Should you buy Vericel stock or one of its competitors? Vericel's main competitors and comparable companies include Cytokinetics (CYTK), Abivax (ABVX), Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), and Ionis Pharmaceuticals (IONS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vericel compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Vericel has a net margin of 7.91% compared to Cytokinetics' net margin of -1,321.12%. Vericel's return on equity of 6.91% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Vericel	7.91%	6.91%	5.02%

Vericel has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	88.91	-$784.96M	-$7.22	N/A
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32

Cytokinetics presently has a consensus target price of $106.06, suggesting a potential upside of 68.58%. Vericel has a consensus target price of $58.40, suggesting a potential upside of 45.64%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cytokinetics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cytokinetics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Vericel has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

In the previous week, Cytokinetics had 7 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Cytokinetics and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Cytokinetics' score of 0.40 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Cytokinetics on 9 of the 14 factors compared between the two stocks.

How does Vericel compare to Abivax?

Abivax (NASDAQ:ABVX) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Vericel has a net margin of 7.91% compared to Abivax's net margin of 0.00%. Vericel's return on equity of 6.91% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Vericel	7.91%	6.91%	5.02%

Vericel has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32

Abivax has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Vericel has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Abivax currently has a consensus price target of $156.69, suggesting a potential upside of 77.76%. Vericel has a consensus price target of $58.40, suggesting a potential upside of 45.64%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Abivax and Abivax both had 4 articles in the media. Abivax's average media sentiment score of 1.32 beat Vericel's score of 0.99 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Vericel beats Abivax on 8 of the 15 factors compared between the two stocks.

How does Vericel compare to Praxis Precision Medicines?

Vericel (NASDAQ:VCEL) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Vericel has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32
Praxis Precision Medicines	$8.55M	848.57	-$303.27M	-$12.93	N/A

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Praxis Precision Medicines' score of 0.24 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market.

Vericel has a net margin of 7.91% compared to Praxis Precision Medicines' net margin of 0.00%. Vericel's return on equity of 6.91% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Vericel presently has a consensus price target of $58.40, indicating a potential upside of 45.64%. Praxis Precision Medicines has a consensus price target of $613.26, indicating a potential upside of 136.00%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

Summary

Vericel beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Vericel (NASDAQ:VCEL) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Vericel has a net margin of 7.91% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32
Spyre Therapeutics	$890K	9,811.99	-$155.20M	-$1.95	N/A

Vericel presently has a consensus target price of $58.40, indicating a potential upside of 45.64%. Spyre Therapeutics has a consensus target price of $109.71, indicating a potential upside of 28.04%. Given Vericel's higher possible upside, research analysts plainly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

80.4% of Spyre Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 18 more articles in the media than Vericel. MarketBeat recorded 22 mentions for Spyre Therapeutics and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Spyre Therapeutics' score of 0.25 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	6 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, suggesting that its share price is 210% more volatile than the broader market.

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Ionis Pharmaceuticals?

Vericel (NASDAQ:VCEL) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Vericel has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32
Ionis Pharmaceuticals	$944M	7.97	-$381.39M	-$3.46	N/A

Vericel has a net margin of 7.91% compared to Ionis Pharmaceuticals' net margin of -64.76%. Vericel's return on equity of 6.91% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vericel currently has a consensus target price of $58.40, indicating a potential upside of 45.64%. Ionis Pharmaceuticals has a consensus target price of $89.20, indicating a potential upside of 97.00%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Ionis Pharmaceuticals had 1 more articles in the media than Vericel. MarketBeat recorded 5 mentions for Ionis Pharmaceuticals and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Ionis Pharmaceuticals' score of -0.14 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

Vericel beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.05B	$3.93B	$7.26B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	85.32	6.96	201.60	20.20
Price / Sales	7.43	1,209.42	581.89	87.91
Price / Cash	72.19	119.49	76.96	53.71
Price / Book	5.72	17.17	11.22	6.33
Net Income	$16.52M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-0.12%	-1.34%	-0.89%	-1.40%
1 Month Performance	5.89%	-8.45%	-4.42%	-3.47%
1 Year Performance	25.90%	14.02%	7.03%	1.18%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	4.2873 of 5 stars	$40.10 +0.1%	$58.40 +45.6%	+22.4%	$2.05B	$276.26M	85.32	398	Positive News
CYTK Cytokinetics	2.6057 of 5 stars	$66.16 +2.3%	$103.37 +56.2%	+4.3%	$8.05B	$88.04M	N/A	673	News Coverage Analyst Forecast Insider Trade
ABVX Abivax	2.5417 of 5 stars	$96.85 +6.4%	$156.69 +61.8%	-2.7%	$7.95B	N/A	N/A	69
PRAX Praxis Precision Medicines	2.6581 of 5 stars	$285.65 +1.7%	$612.42 +114.4%	+374.5%	$7.84B	$8.55M	N/A	110	Analyst Forecast
SYRE Spyre Therapeutics	2.7829 of 5 stars	$85.79 +0.1%	$109.69 +27.9%	+304.8%	$7.54B	$890K	N/A	112

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. CYTK, ABVX, PRAX, SYRE, and IONS

How does Vericel compare to Cytokinetics?

Summary

How does Vericel compare to Abivax?

Summary

How does Vericel compare to Praxis Precision Medicines?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

How does Vericel compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. CYTK, ABVX, PRAX, SYRE, and IONS

How does Vericel compare to Cytokinetics?

Is CYTK or VCEL more profitable?

Which has higher earnings & valuation, CYTK or VCEL?

Do analysts recommend CYTK or VCEL?

Which has more risk & volatility, CYTK or VCEL?

Does the media favor CYTK or VCEL?

Summary

How does Vericel compare to Abivax?

Is ABVX or VCEL more profitable?

Which has stronger earnings and valuation, ABVX or VCEL?

Which has more volatility and risk, ABVX or VCEL?

Do analysts recommend ABVX or VCEL?

Does the media refer more to ABVX or VCEL?

Do institutionals and insiders have more ownership in ABVX or VCEL?

Summary

How does Vericel compare to Praxis Precision Medicines?

Do institutionals and insiders have more ownership in VCEL or PRAX?

Which has stronger earnings & valuation, VCEL or PRAX?

Does the media prefer VCEL or PRAX?

Which has more volatility & risk, VCEL or PRAX?

Is VCEL or PRAX more profitable?

Do analysts prefer VCEL or PRAX?

Summary

How does Vericel compare to Spyre Therapeutics?

Is VCEL or SYRE more profitable?

Which has stronger earnings and valuation, VCEL or SYRE?

Do analysts rate VCEL or SYRE?

Do institutionals & insiders believe in VCEL or SYRE?

Does the media prefer VCEL or SYRE?

Which has more volatility & risk, VCEL or SYRE?

Summary

How does Vericel compare to Ionis Pharmaceuticals?

Which has better valuation and earnings, VCEL or IONS?

Is VCEL or IONS more profitable?

Do insiders & institutionals believe in VCEL or IONS?

Do analysts rate VCEL or IONS?

Does the media prefer VCEL or IONS?

Which has more risk and volatility, VCEL or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools